Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma
Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are considered a first-line treatment in the management of glaucoma and have the best efficacy in reducing intraocular pressure....
Main Authors: | Lin Zhou, Wenyi Zhan, Xin Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1015338/full |
Similar Items
-
Genotype and Phenotype Influence the Personal Response to Prostaglandin Analogues and Beta-Blockers in Spanish Glaucoma and Ocular Hypertension Patients
by: Valeria Opazo-Toro, et al.
Published: (2023-01-01) -
Impact of prostaglandin glaucoma drops on platelet-activating factor action: an in vitro study
by: Moschos MM, et al.
Published: (2016-12-01) -
PROSTAGLANDINS ANALOGUES DURING CATARACT PHACOEMULSIFICATION ON THE BACKGROUND OF PRIMARY GLAUCOMA
by: I. E. Ioshin, et al.
Published: (2016-11-01) -
Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis
by: Yuanzhi Liu, et al.
Published: (2019-06-01) -
The changes of corneal biomechanical properties with long-term treatment of prostaglandin analogue measured by Corvis ST
by: Na Wu, et al.
Published: (2020-10-01)